drugset / Trial / NCT01511198
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
RandomizedParallel-groupDouble-blindTreatment
Summary
This trial is conducted in the United States of America (USA). The aim of this trial is to determine the dose-response relationship for body weight and five escalating doses of NNC 90-1170 (liraglutide) in subjects with type 2 diabetes previously treated with an oral hypoglycemic agent (OHA).
Timeline
- Start
- 2001-02
- Primary completion
- 2001-10
- Completion
- 2001-10
Publications
- Results Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O; Liraglutide Dose-Response Study Group. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes. Diabet Med. 2005 Aug;22(8):1016-23. doi: 10.1111/j.1464-5491.2005.01567.x.
- Results Jensen TM, Saha K, Steinberg WM. Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care. 2015 Jun;38(6):1058-66. doi: 10.2337/dc13-1210. Epub 2014 Dec 12.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Liraglutide | Peptide | 0.045 mg | Subcutaneous |
| Subject | Liraglutide | Peptide | 0.225 mg | Subcutaneous |
| Subject | Liraglutide | Peptide | 0.45 mg | Subcutaneous |
| Subject | Liraglutide | Peptide | 0.6 mg | Subcutaneous |
| Subject | Liraglutide | Peptide | 0.75 mg | Subcutaneous |
| Comparator | Metformin | Small molecule | 1000 mg | Oral |